Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.59 |
| ▸ | CA1 | P00915 | 3/20 | 0.54 |
| ▸ | CA2 | P00918 | 3/20 | 0.54 |
| ▸ | CA12 | O43570 | 1/20 | 0.54 |
| ▸ | CA3 | P07451 | 1/20 | 0.54 |
| ▸ | CA6 | P23280 | 1/20 | 0.54 |
| ▸ | CA5A | P35218 | 1/20 | 0.54 |
| ▸ | CA7 | P43166 | 1/20 | 0.54 |
| ▸ | CA9 | Q16790 | 1/20 | 0.54 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.48 |
| ▸ | MMP1 | P03956 | 1/20 | 0.48 |
| ▸ | MMP2 | P08253 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1586 | 0.97 | GAA (0.62) | GAACA1CA2CA12CA3 | |
| SCHEMBL31231738 | 0.97 | GAA (0.62) | GAACA1CA2CA12CA3 | |
| Methane SCHEMBL29250211 | 0.95 | GAA (0.59) | GAACA1CA2CA12CA3 | |
| Water SCHEMBL6162445 | 0.95 | GAA (0.59) | GAACA1CA2CA12CA3 | |
| Hydrochloric Acid SCHEMBL29967262 | 0.95 | GAA (0.59) | GAACA1CA2CA12CA3 | |
| SCHEMBL31058081 | 0.95 | GAA (0.59) | GAACA1CA2CA12CA3 | |
| SCHEMBL1584414 | 0.95 | GAA (0.59) | GAACA1CA2CA12CA3 | |
| Hydrochloric Acid SCHEMBL2833772 | 0.95 | GAA (0.59) | GAACA1CA2CA12CA3 | |
| Bromide SCHEMBL27747573 | 0.95 | GAA (0.59) | GAACA1CA2CA12CA3 | |
| SCHEMBL27998323 | 0.95 | GAA (0.59) | GAACA1CA2CA12CA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190352511-A1 | LANTHANIDE COMPLEXES COMPRISING DENDRIMERS | UNIVERSITE D'ORLEANS (FR) | 2019-11-21 | — | — | US | disclosed |
| EP-3568401-A1 | LANTHANIDE COMPLEXES COMPRISING DENDRIMERS | Universite D'Orleans (FR) | 2019-11-20 | — | — | EP | disclosed |
| EP-1463718-A1 | 2-SUBSTITUTED THIAZOLIDINONE AND OXAZOLIDINONE DERIVATIVES FOR THE INHIBITION OF PHOSPHATASES AND THE TREATMENT OF CANCER | Incyte San Diego Incorporated (US) | 2004-10-06 | — | — | EP | disclosed |
| US-20040097566-A1 | 2-Substituted thiazolidinone and oxazolidinone derivatives for the inhibition of phosphatases and the treatment of cancer | INCYTE SAN DIEGO INCORPORATED | 2004-05-20 | — | — | US | disclosed |
| WO-2003050098-A1 | 2-SUBSTITUTED THIAZOLIDINONE AND OXAZOLIDINONE DERIVATIVES FOR THE INHIBITION OF PHOSPHATASES AND THE TREATMENT OF CANCER | INCYTE SAN DIEGO INCORPORATED (US) | 2003-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190352511-A1 | LANTHANIDE COMPLEXES COMPRISING DENDRIMERS | CLTA, CLTB, CA12 | GAA 1247/4885CA1 58/4885CA2 49/4885 |
| US-20040097566-A1 | 2-Substituted thiazolidinone and oxazolidinone derivatives for the inhibition of phosphatases and the treatment of cancer | PTPA, PTPRC, PTPRCAP | GAA 1045/4885CA1 952/4885CA2 192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.